Deals channel feed

Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

Last year
R&D

Ot­su­ka to ac­quire psy­che­del­ic drug dis­cov­ery out­fit Mind­set Phar­ma

Last year

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

Last year
Startups
Pharma

Up­dat­ed: No­vo Nordisk bags new obe­si­ty tar­get in lat­est biotech ac­qui­si­tion, inks R&D deal with spin­out

Last year

WHO se­cures three li­cens­ing deals to boost Covid vac­cine and as­say prod­uct op­tions

Last year
Coronavirus
Manufacturing

Celu­lar­i­ty signs on to do con­tract re­search for Re­gen­eron

Last year

Up­dat­ed: As sales con­tin­ue to slide, Catal­ent reach­es deal with ac­tivist to add board seats and con­duct re­view

Last year
Outsourcing
Manufacturing

Re­silience part­ners with Sau­di-based Lif­era to build bio­man­u­fac­tur­ing site

Last year
Pharma
Manufacturing

Ve­rastem On­col­o­gy se­cures col­lab­o­ra­tion with Gen­Fleet Ther­a­peu­tics, po­ten­tial­ly worth up to $600M+

Last year

Ab­cam agrees to $5.7B sale to Dana­her amid founder's push for a board seat

Last year

SPAC merg­er falls through be­tween Wilbur Ross' blank check com­pa­ny and Alzheimer's play­er

Last year

Roy­al­ty Phar­ma pays Fer­ring $300M for 5% roy­al­ty on sales of can­cer gene ther­a­py Ad­sti­ladrin

Last year

Ex­clu­sive: As­traZeneca and Vaxess de­vel­op­ing skin patch mR­NA vac­cines for pan­dem­ic flu

Last year
R&D

In­ver­sa­go was work­ing to­ward a po­ten­tial 2024 IPO, but No­vo’s in­ter­est won out. CB1 biotechs hope to ride the wave

Last year
Pharma
In Focus

Leo Phar­ma spend­ing $14M up­front to ac­quire Tim­ber

Last year
R&D

Skye ac­quires Bird Rock Bio, weeks af­ter No­vo Nordisk says it will buy a CB1 de­vel­op­er

Last year
Financing
Startups

Mod­er­na and CARs­gen team up on CAR-T cell ther­a­py and mR­NA can­cer vac­cine com­bo

Last year

SPAC Ash­ing­ton In­no­va­tion plans to ac­quire dor­mant biotech Celixir and lead heart fail­ure pro­gram for $172M

Last year
R&D

Day One Bio­phar­ma­ceu­ti­cals inks re­search col­lab­o­ra­tion with Swedish biotech

Last year
R&D

Gilead dish­es out $66M for San Diego biotech's 'ten­ta­cles' in can­cer, in­flam­ma­tion

Last year
Startups

Ger­man gener­ic drug com­pa­ny Sta­da in ear­ly talks over pos­si­ble $11B sale, ex­ec con­firms

Last year

Am­gen, Hori­zon urge judge to up­hold con­sti­tu­tion­al­i­ty ar­gu­ments against FTC

Last year
Pharma

Har­mo­ny looks to buy rare dis­ease drug de­vel­op­er in deal worth up to $200M

Last year
Pharma

Ra­dius Phar­ma sells off part of its roy­al­ties, mile­stones in breast can­cer drug Orser­du

Last year
Pharma
First page Previous page 29303132333435 Next page Last page
A service from the Financial Times